
 **Multidisciplinary Reviews in Malignant Hematology - Multiple Myeloma 2024 | 09/20/2024 7:30 AM OFP Gilmour Center**

The field of Plasma Cell Disorders (Multiple Myeloma), its diagnosis, and multidisciplinary management is a constantly evolving field. Over the recent past we have witnessed how an enhanced classification system has helped us better assess disease biology/function for earlier therapeutic intervention, while a deeper understanding of the underlying disease mechanisms has in turn informed us of the ways in which we can devise management strategies using traditional, targeted, immunomodulatory, and cellular therapies. This update is intended to enhance our understanding of the mechanisms behind the development and progression of plasma cell disorders, in particular multiple myeloma, the ways in which they are now being treated, their resistance pathways, and the ever-increasing novel management concepts being tested in the lab and clinic. The hope is that we can come away from this conference with a better understanding of these disorders and use this knowledge to both further the field and better help in the care of our patients.

**Program Goal**

1 Understand the morphologic and cytogenetic evaluation of Multiple Myeloma

2 Evaluate multi-modality management of plasmacytoma, as well as newly diagnosed and relapsed multiple myeloma.

3 Assess the sequencing of T-cell directed therapy in Multiple Myeloma

4 Conceptualize how newer treatment modalities might modify standards of care in the near future

**Target Audience** Hematology / Oncology

**Faculty**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Mira M Shah, MD | Faculty | Nothing to disclose - 06/11/2024 |
| Philip Kuriakose, MD | Course Director, Faculty | Advisor-CSL Behring|Advisor-Pfizer|Advisor-Astrazeneca|Advisor-Sanofi - 01/16/2024 |
| Vrushali Dabak, MD | Co-Director, Faculty | Nothing to disclose - 07/05/2024 |
| Edward Peres, MD | Faculty | Nothing to disclose - 07/03/2024 |
| Brandon M Shaw, PhD | Faculty | Nothing to disclose - 07/02/2024 |
| Kedar V Inamdar, MD, PhD | Faculty | Independent Contractor (included contracted research)-Beckman Coulter Inc - 07/17/2024 |
| Shatha Farhan, MD | Faculty | Nothing to disclose - 04/08/2024 |
| Olena Kis, PhD | Faculty | Nothing to disclose - 06/17/2024 |
| Jawad Sheqwara, MD | Co-Director, Faculty | Advisor-Pfizer|Advisor-Astrazeneca|Advisor-Janssen|Advisor-Incyte|Speakers Bureau-Seagen (Relationship has ended)|Honoraria-cardinal health|Honoraria-Aptitude|Honoraria-curio sciences|Honoraria-targeted oncology - 07/16/2024 |
| Juan Gomez-Gelvez, MD | Faculty | Nothing to disclose - 07/10/2024 |
| Crystal M Gyiraszin, MS | CME Reviewer | Nothing to disclose - 02/20/2024 |
| Alicia Bias, Bachelors | Activity Coordinator | Nothing to disclose - 06/24/2024 |
| Denise Brooks, MBA | CME Specialist | Nothing to disclose - 06/26/2024 |
| Kisha McPherson, MHSA | Activity Coordinator | Nothing to disclose - 03/12/2024 |
| Wei Zhao, MD-Fellow | Faculty | Nothing to disclose - 01/12/2024 |
| Markie Zimmer, MD | Faculty | Nothing to disclose - 06/11/2024 |
| Morie Gertz, MD | Faculty | Consulting Fee-AbbVie - 06/13/2024 |

All of the relevant financial relationships listed for these individuals have been mitigated.

**ACCREDITATION STATEMENT:** Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**DESIGNATION STATEMENT:** Henry Ford Health designates this live course for a maximum of 5.00 *AMA PRA Category 1 Credit(s) TM*. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT:** In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose relevant financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All relevant financial relationships have been mitigated prior to the commencement of the activity.

**ACCESSIBILITY STATEMENT:** Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator Alicia Bias at abias1@hfhs.org If you have questions, please email Alicia Bias at abias1@hfhs.org. Please allow a minimum of 3 days to process this request.